{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pasqualini R"],"funding":["Gillson-Longenbaugh Foundation, the Marcus Foundation, the Prostate Cancer Foundation, and the National Institutes of Health","NIDDK NIH HHS","NCI NIH HHS","NIGMS NIH HHS","NIH HHS"],"pagination":["2411-21"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4490036"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["121(14)"],"pubmed_abstract":["<h4>Background</h4>Receptors in tumor blood vessels are attractive targets for ligand-directed drug discovery and development. The authors have worked systematically to map human endothelial receptors (\"vascular zip codes\") within tumors through direct peptide library selection in cancer patients. Previously, they selected a ligand-binding motif to the interleukin-11 receptor alpha (IL-11Rα) in the human vasculature.<h4>Methods</h4>The authors generated a ligand-directed, peptidomimetic drug (bone metastasis-targeting peptidomimetic-11 [BMTP-11]) for IL-11Rα-based human tumor vascular targeting. Preclinical studies (efficacy/toxicity) included evaluating BMTP-11 in prostate cancer xenograft models, drug localization, targeted apoptotic effects, pharmacokinetic/pharmacodynamic analyses, and"],"journal":["Cancer"],"pubmed_title":["Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study."],"pmcid":["PMC4490036"],"funding_grant_id":["CA140388","S10 OD012304","P50 CA090270","R01 DK067683","P50 CA140388","U54 GM104942"],"pubmed_authors":["Giordano RJ","Logothetis CJ","Baze WB","Cardo-Vila M","Lobb RR","Arap W","Christianson DR","Hajitou A","Wen S","Barnhart KF","Navone NM","Pasqualini R","Marcott VD","Troncoso P","Hoang AG","Hawke DH","Efstathiou E","Driessen WH","Do KA","Millikan RE"],"additional_accession":[]},"is_claimable":false,"name":"Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.","description":"<h4>Background</h4>Receptors in tumor blood vessels are attractive targets for ligand-directed drug discovery and development. The authors have worked systematically to map human endothelial receptors (\"vascular zip codes\") within tumors through direct peptide library selection in cancer patients. Previously, they selected a ligand-binding motif to the interleukin-11 receptor alpha (IL-11Rα) in the human vasculature.<h4>Methods</h4>The authors generated a ligand-directed, peptidomimetic drug (bone metastasis-targeting peptidomimetic-11 [BMTP-11]) for IL-11Rα-based human tumor vascular targeting. Preclinical studies (efficacy/toxicity) included evaluating BMTP-11 in prostate cancer xenograft models, drug localization, targeted apoptotic effects, pharmacokinetic/pharmacodynamic analyses, and","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jul","modification":"2026-05-30T10:09:44.076Z","creation":"2019-03-27T01:54:25Z"},"accession":"S-EPMC4490036","cross_references":{"pubmed":["25832466"],"doi":["10.1002/cncr.29344"]}}